ArticleVaccine2023
In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer.
Article in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- Engineered nanovaccines for prophylactic and therapeutic immunotherapy against cancer and infectious disease.Human vaccines & immunotherapeutics · 2026Review
- Advances in Breast Cancer Research: Immunological, Pathological, and Pharmacological Perspectives for Improving Patient Outcomes.International journal of molecular sciences · 2026Review
- mRNA cancer vaccines: delivery strategies, immune modulation, and clinical translation.Frontiers in pharmacology · 2026Review
- Breaking Barriers: Immune Checkpoint Inhibitors in Breast Cancer.Pharmaceutics · 2025Review
- mRNA-based immunotherapy platform targeting endometrial cancer.Journal of translational medicine · 2025Article
- The HER2 target for designing novel multi-peptide vaccine against breast cancer using immunoinformatics and molecular dynamic simulation.Biochemistry and biophysics reports · 2025Article
- Review
- A Reverse Vaccinology and Immunoinformatic Approach for the Designing of a Novel mRNA Vaccine Against Stomach Cancer Targeting the Potent Pathogenic Proteins ofBioinformatics and biology insights · 2025Article
- Promising future of breast cancer vaccine asking for multidisciplinary collaboration: a literature review.Frontiers in cell and developmental biology · 2025Review
- Design of a Multiepitope Pan-Proteomic mRNA Vaccine Construct Against African Swine Fever Virus: A Reverse Vaccinology Approach.Veterinary medicine international · 2025Article
- Advances in mRNA LNP-Based Cancer Vaccines: Mechanisms, Formulation Aspects, Challenges, and Future Directions.Journal of personalized medicine · 2024Review
- mRNA-based therapeutic strategies for cancer treatment.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- AutoEpiCollect, a Novel Machine Learning-Based GUI Software for Vaccine Design: Application to Pan-Cancer Vaccine Design Targeting PIK3CA Neoantigens.Bioengineering (Basel, Switzerland) · 2024Article
- The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases.Heliyon · 2024Review
- mRNA vaccines and their delivery strategies: A journey from infectious diseases to cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- Emerging strategies to overcome ovarian cancer: advances in immunotherapy.Frontiers in pharmacology · 2024Review
- Multimodal ultrasound plus tumor markers demonstrates a high value in enhanced diagnosis of breast cancer.American journal of translational research · 2024Article
- MUC1 and MUC16: critical for immune modulation in cancer therapeutics.Frontiers in immunology · 2024Review
- Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment.Pharmaceutics · 2023Article
- From bench to bedside via bytes: Multi-omic immunoprofiling and integration using machine learning and network approaches.Human vaccines & immunotherapeutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Somatic mutation-derived neoantigens are associated with patient survival in breast and ovarian cancer. These neoantigens are targets for cancer, as shown by the implementation of neoepitope peptides as cancer vaccines. The success of cost-effective multi-epitope mRNA vaccines against SARS-Cov-2 in the pandemic established a model for reverse vaccinology. In this study, we aimed to develop an in silico pipeline designing an mRNA vaccine of the CA-125 neoantigen against breast and ovarian cancer, respectively. Using immuno-bioinformatics tools, we predicted cytotoxic CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.